Bayer stock heads into the open after a 0.9 percent Xetra loss

At the close on September 10, 2026, Bayer stock finished Xetra trading at EUR 48.81, down about 0.9 percent from the previous close, as analyst actions and a new FDA cancer drug approval framed sentiment. The shares trailed the DAX and traded between roughly EUR 48.7 and EUR 49.3.

Bayer stock closed at EUR 48.81 on Xetra on September 10, 2026, losing about 0.9 percent from the previous session’s EUR 49.26 finish. The move left the shares trading just below the EUR 49 mark in a moderately volatile session.

September 10, 2026 in numbers

Bayer AG (ISIN DE000BAY0017, Xetra: BAYN) ended the Xetra session on September 10, 2026 at EUR 48.81, compared with a prior close of EUR 49.26, implying a decline of roughly 0.9 percent in euro terms according to Xetra closing data cited by Welt. The same wrap noted that the stock had previously closed at EUR 49.26, underscoring the step down at the latest close.Welt Intraday, Bayer shares traded in a corridor just under EUR 49, with finanzen.ch citing Xetra data that showed levels around EUR 48.99 at 12:28 on September 10, 2026, after an intraday low near EUR 48.72 and an opening price around EUR 49.20 on a volume of roughly 509,085 shares.finanzen.ch These figures place the close near the lower end of the day’s range, while remaining consistent with a tight band between roughly EUR 48.7 and EUR 49.3.

In the broader market backdrop, regionalheute.de reported that the DAX weakened into the September 10, 2026 close as rising prices for oil and gas weighed on sentiment.regionalheute.de Against that environment, Bayer’s roughly 0.9 percent decline on Xetra meant the stock underperformed a broadly softer home index, adding a cyclical and market-related component to the move in addition to company-specific news.

Analyst calls and FDA approval shape today’s focus

Todays session is framed by fresh analyst actions and regulatory news that surfaced on or just before September 10, 2026. Deutsche Bank Research reiterated a buy rating on Bayer with a target price of EUR 60, as reported by dpa-AFX via boerse.de on September 10, 2026, keeping an upside case in focus despite recent volatility.boerse.de In parallel, ad-hoc-news highlighted that Bayer stock was trading modestly below both the Deutsche Bank target and a raised Barclays target of EUR 70.00, with the Barclays stance also set at buy.Ad-hoc-news This analyst support provides a valuation backdrop that investors may weigh against the recent Xetra close.

Ad-hoc-news also pointed to a fresh US Food and Drug Administration approval for Bayer’s lung cancer drug sevabertinib, noting that the decision strengthens the pharmaceuticals pipeline in the oncology segment.Ad-hoc-news With the approval already public ahead of the European and US sessions on September 11, 2026, investors can factor the regulatory milestone, the updated analyst targets and the recent underperformance versus the DAX into their view of Bayer stock today.